Table 1 Patient characteristics

Total

106 (100)

Age at diagnosis, median

57

FIGO stage

I

8 (8)

II

8 (8)

III

76 (71)

IV

14 (13)

Histopathological subtype

Serous*

94 (89)

Endometrioid

5 (4)

Serous + clear cell (mixed)

1 (1)

Transitiocellular carcinoma

1 (1)

Carcinosarcoma

1 (1)

Adenocarcinoma

1 (1)

Borderline (with invasive implants)

3 (3)

Number of prior chemotherapy regimens

Median

4

Range

2 - 7

Interval from last chemotherapy regimens

Median

1.8

Range

0.3-14.7 months

Bevacizumab infusions

Median

4.5

Mean

7.1

Range

1 – 64**

≤ 2 cycles

22 (21)

≥ 9 cycles

29 (27)

Performance status at start of bevacizumab treatment

0

40 (38)

1

52 (49)

2

13 (12)

3

1 (1)

Baseline VEGF, median (range)

504 (27–1847)

Baseline PDGF-AA, median (range)

2074.25 (207 – 5476.5)

Baseline PDGF-BB, median (range)

7789 (670–28487)

Baseline FGF2, median (range)

60 (8–234)